StudyManager, Inc., a healthcare IT company and creator of StudyManager clinical trial management software (CTMS), today announced the release of Reveal version 3.1, expanding the recruitment, financial, and reporting capabilities of its clinical trial management software (CTMS) for sites and hospitals.
Expanded Business Management and Productivity Tools for Research Sites
Reveal 3.1 allows research organizations to centralize study information, organize research activities, and increase recruitment and financial performance.
Strong Market Response to Reveal and Personalized Service
StudyManager has seen a 40% increase in Reveal sales in the second half of 2010, compared to the first half of the year. Growth is expected to accelerate further in 2011, as StudyManager pairs its Reveal cloud solution with an on-premises option and continues to expand features and services. With Reveal, each customer gets a dedicated trainer who builds a training plan around the customer’s needs and objectives.
Improving the Research Site "Bottom Line"
Reveal is built on the feedback and experience of StudyManager's customers, and the company's nearly 20 years in the field. Then, Reveal's decision support tools can have a big impact on the bottom line, helping sites negotiate more favorable contracts, make enrollment course corrections, and ensure they get paid for all study activity.
Reveal features focus on helping sites centralize study information, and:
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.